Log In
Print
BCIQ
Print
Print this Print this
 

etrolizumab (RG7413)

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionRecombinant humanized mAb targeting integrin beta(7)
Molecular Target Integrin beta(7)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation

Partner

Genentech Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today